• 1
    Ettinger B, Pressman A, Scheim J, Chan J, Silver P, Connolly N 1998 Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discrimination. J Manag Care Pharm 4:488492.
  • 2
    Recker RR, Gallagher R, MacCosbe PE 2005 Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856861.
  • 3
    Tashjian AH Jr, Chabner BA 2002 Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women. J Bone Miner Res 17:11511161.
  • 4
    Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore M, Ma L, Nold JB 2002 Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30:312321.
  • 5
    Vahle JL, Long GG, Sandusky G, Westmore M, Ma YL, Sato M 2004 Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose. Toxicol Pathol 32:426438.
  • 6
    Wilker CE, Jolette J, Smith SY, Doyle N, Hardisty JF, Metcalf AJ, Marriott JB, Fox J, Wells DS 2004 A no observable carcinogenic effect dose-level identified in Fisher 344 rats following daily treatment with PTH (1-84) for 2 years: Role of the C-terminal PTH receptor. J Bone Miner Res 19S1:S98.
  • 7
    Bagan JV, Murillo J, Jimenez Y, Poveda R, Milian MA, Sanchis JM, Silvestre FJ, Scully C 2005 Avascular jaw osteonecrosis in association with cancer chemotherapy: Series of 10 cases. J Oral Pathol Med 34:120123.
  • 8
    Purcell PM, Boyd IW 2005 Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182:417418.
  • 9
    Vannucchi AM, Ficarra G, Antonioli E, Bosi A 2005 Osteonecrosis of the jaw associated with zoledronate therapy in a patient with multiple myeloma. Br J Haematol 128:738.
  • 10
    Betancourt M, Wirfel KL, Raymond AK, Yasko AW, Lee J, Vassilopoulou-Sellin R 2003 Osteosarcoma of bone in a patient with primary hyperparathyroidism: A case report. J Bone Miner Res 18:163166.
  • 11
    Wiig JN, Bakken TS 1971 Hyperparathyroidism with multiple malignant tumors of bone with giant cells. A case report. Acta Chir Scand 137:391393.
  • 12
    Smith J, Huvos AG, Chapman M, Rabbs C, Spiro RH 1997 Hyperparathyroidism associated with sarcoma of bone. Skeletal Radiol 26:107112.
  • 13
    Jimenez C, Yang Y, Kim H-W, Al-Sagier F, Berry DA, El-Naggar AK, Patel S, Vassilopoulou-Sellin R, Gagel RF 2005 Primary hyperparathyroidism and osteosarcoma: Examination of a large cohort identifies three cases of osteosarcoma. J Bone Miner Res 20:15621568.
  • 14
    Pendlebury SC, Bilous M, Langlands AO 1995 Sarcomas following radiation therapy for breast cancer: A report of 3 cases and a review of the literature. Int J Radiat Oncol Biol Phys 31:405410.
  • 15
    Hortobagyi GN, Theriault RL, Porter L, Blyney D, Lipton A, Sinoff C, Wheeler H, Simeone JF, Seaman J, Knight RD 1996 Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:17851791.
  • 16
    Rodman GD 2004 Mechanisms of Bone Metastasis. N Engl J Med 350:16551664.
  • 17
    Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, Chirgwin JM 2005 Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer 5(Suppl 2):4653.
  • 18
    Henderson MA, Danks JA, Mosley JM, Slavin JL, Harris TL, McKinlay MR, Hopper JL, Martin TJ 2001 Parathyroid hormone-related protein production by breast cancers, improved survival, and reduced bone metastases. J Natl Cancer Inst 93:234237.
  • 19
    Prince RL, Sipos A, Hossain A, Syversen U, Ish-shalom S, Marcinowska E, Halse J, Lindsay R, Mitlak B 2005 Sustained non-vertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 10:15071513.
  • 20
    Mitlak BH 2002 Parathyroid hormone as a therapeutic agent. Curr Opin Pharmacol 2:694699.
  • 21
    Miller PD, Bilezikian JP, Deal C, Harris ST, Pacifici R 2004 Clinical use of teriparatide in the real world: Initial insights. Endocr Pract 10:139148.
  • 22
    Hodsman AB, Bauer DC, Dempster D, Dian L, Hanley DA, Harris ST, Kendler D, McClung MR, Miller PD, Olszynski WP, Orwoll E, Yuen CK 2005 Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 26:688703.
  • 23
    Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA 2003 The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:917.
  • 24
    Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP 2000 Parathyroid hormone as a therapy for idiopathic osteoporosis in men: Effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:30693076.
  • 25
    Bilezikian JP, Kurland ES 2001 Therapy of male osteoporosis with parathyroid hormone. Calcif Tissue Int 69:248251.
  • 26
    Kaufman JM, Orwoll E, Goemaere S, San Martin J, Hossain A, Dalsky GP, Lindsay R, Mitlak BH 2004 Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: Treatment and discontinuation of therapy. Osteoporos Int 16:510516.
  • 27
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 1998 Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 102:16271633.
  • 28
    Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud CD 2000 Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: Results of a randomized controlled clinical trial. J Bone Miner Res 15:944951.
  • 29
    Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster JY, Stepan JJ, Myers SL, Mitlak BH 2004 Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:20242030.
  • 30
    Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555565.
  • 31
    Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:12161226.
  • 32
    Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:12071215.
  • 33
    Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF 2005 Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:39703977.
  • 34
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962970.
  • 35
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R 2005 Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 353:566576.
  • 36
    Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R 2005 Effects of PTH rechallenge 1 year after the first PTH course in patients on long-term alendronate. J Bone Miner Res 20S1:S21.
  • 37
    Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Helix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiodt CB, Sorensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaisse JM, Engsig MT, Karsdal MA 2004 The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation. J Bone Miner Res 19:11441153.
  • 38
    Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang M-S, Lüthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Eliott R, Colombero A, Tan H-L, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Amgen EST Program, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309319.
  • 39
    Liu X, Geng Z, Kaufman S, Tau HL, Morony S, Grisanti M, Hoffman K, Ominsky M, Kostenik PJ 2005 RANKL inhibition improves cortical bone geometry by stimulating periosteal bone formation in ovariectomized rats. J Bone Miner Res 20S1:S57.
  • 40
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D, Cosman F 1997 Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 41
    Fogelman I, Christiansen C, Spector T, Fraser W, Fordham J 2005 Safety and efficacy of PTH(1-84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study. J Bone Miner Res 20S1:S21.
  • 42
    Ma YL, Bryant HU, Zeng QQ, Schmidt A, Hoover J, Cole HW, Yao W, Jee WSS, Sato M 2003 New bone formation with teriparatide (hPTH(1-34)) is not retarded by long-term pretreatment with alendronate, estrogen or raloxifene in ovariectomized rats. Endocrinology 144:20082015.
  • 43
    Hodsman AB, Drost D, Fraher LJ, Holdsworth D, Thornton M, Hock J, Bryant H, Wilson PH 1999 The addition of a raloxifene analog (LY117018) allows for reduced PTH(1-34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res 14:675679.
  • 44
    Ettinger B, San Martin J, Crans G, Pavo I 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745751.
    Direct Link:
  • 45
    Cosman F, Nieves J, Barbuto N, Zion M, Lindsay R 2004 Parathyroid hormone added to raloxifene and subsequent maintainance of BMD gain with raloxifene alone. J Bone Miner Res 19S1:S98.
  • 46
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH 2005 Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: Results from a 6-month double-blind placebo-controlled trial. J Bone Miner Res 20:19051911.
  • 47
    Gallagher JC, Goldgar D 1990 Treatment of postmenopausal osteoporosis with high doses of synthetic calcitriol. A randomized controlled study. Ann Intern Med 113:649655.
  • 48
    Brown AJ, Dusso AS, Slatopolsky E 2002 Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 17(Suppl 10):1019.
  • 49
    Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:14341441.
  • 50
    Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ 2000 Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab 85:21292134.
  • 51
    Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP 2004 The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide. Osteoporos Int 15:992997.
  • 52
    Lindsay R, Nieves J, Formica C, Henneman E, Woelfert L, Shen V, Dempster D 1997 Randomized controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet 350:550555.
  • 53
    Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr 1980 Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: A multicentre trial. BMJ 280:13401344.
  • 54
    Horwitz M, Stewart A, Greenspan SL 2000 Sequential parathyroid hormone/alendronate therapy for osteoporosis-robbing Peter to pay Paul. J Clin Endocrinol Metab 85:21272128.
  • 55
    Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL 2003 Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res 18:539543.
  • 56
    Locklin RM, Khosla S, Turner RT, Riggs BL 2003 Mediators of the biphasic responses of bone to intermittent and continuous administration of parathyroid hormone. J Cell Biochem 89:180190.
  • 57
    Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G 2005 Unique coexpression in osteoblasts of broadly expressed genes account for the spatial restriction of ECM mineralization to bone. Gene Dev 19:10931104.
  • 58
    Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD 2000 Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434442.
  • 59
    Martin TJ, Sims NA 2005 Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11:7681.
  • 60
    Centrella M, Horowitz MC, Wozney JM, McCarthy TL 1994 Transforming growth factor-beta gene family members and bone. Endocr Rev 15:2739.
  • 61
    Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT 2003 Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841846.
  • 62
    Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB Jr 2003 Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone - (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 88:42144220.
  • 63
    Andreassen TT, Ejersted C, Oxlund H 1999 Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing rat fractures. J Bone Miner Res 14:960968.
  • 64
    Holzer G, Majeska RJ, Lundy MW, Hartke JR, Einhorn TA 1999 Parathyroid hormone enhances fracture healing. A preliminary report. Clin Orthop Relat Res 366:258263.
  • 65
    Nakajima A, Shimoji N, Shiomi K, Shimizu S, Moriya H, Einhorn TA, Yamazaki M 2002 Mechanisms for the enhancement of fracture healing in rats treated with intermittent low-dose human parathyroid hormone (1-34). J Bone Miner Res 17:20382047.
  • 66
    Komatsubara S, Mori S, Mashiba T, Nonaka K, Seki A, Akiyama T, Miyamoto K, Cao Y, Manabe T, Norimatsu H 2005 Human parathyroid hormone (1-34) accelerates the fracture healing process of woven to lamellar bone replacement and new cortical shell formation in rat femora. Bone 36:678687.
  • 67
    Skripitz R, Aspenberg P 2001 Early effect of parathyroid hormone (1-34) on implant fixation. Clin Orthop Relat Res 392:427432.
  • 68
    Skripitz R, Aspenberg P 2001 Implant fixation enhanced by intermittent treatment with parathyroid hormone. J Bone Joint Surg Br 83:437440.
  • 69
    Shirota T, Tashiro M, Ohno K, Yamaguchi A 2003 Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomized rats. J Oral Maxillofac Surg 61:471480.